SARS-CoV-2 viroporins mediate cytokine storm via mitochondrial permeability transition pore

NewsGuard 100/100 Score

In a recent study posted to the bioRxiv* preprint server, researchers demonstrated that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viroporins precipitate cytokine storm via the alteration of mitochondrial physiology in severe coronavirus disease 2019 (COVID-19).

Study: SARS-CoV-2 Viroporins Activate The NLRP3-Inflammasome Via The Mitochondrial Permeability Transition Pore. Image Credit: CROCOTHERY/Shutterstock
Study: SARS-CoV-2 Viroporins Activate The NLRP3-Inflammasome Via The Mitochondrial Permeability Transition Pore. Image Credit: CROCOTHERY/Shutterstock

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Following the emergence of SARS-CoV-2 in November 2019, nearly 427 million confirmed cases of COVID-19 and 5.89 million SARS-CoV-2-related deaths have been reported so far globally. The severe form of COVID-19 manifests as acute respiratory distress syndrome, respiratory failure, pneumonia, and cytokine storm, leading to multi-organ system failure.

A major cause of mortality associated with COVID-19 is cytokine storm-induced stimulation of the host nonspecific immunological responses. Nevertheless, the mechanism by which SARS-CoV-2 stimulates the nucleotide-binding domain, leucine-rich repeat family, pyrin domain-containing 3-I (NLRP3-I)-inflammasome, which leads to the cytokine storm, remains unknown.

About the study

In the present study, the scientists elucidated the process by which SARS-CoV-2 activates the inflammatory responses leading to the cytokine storm during COVID-19 by evaluating SARS-CoV-2 viroporin proteins envelope (E) and Orf3a, collectively called 2-E+2-3a.

The team monitored the secretion of mature interleukin-1β (IL-1β) from macrophages derived from a human acute monocytic leukemia-derived cell line (THP1), and the NLRP3, pro-IL-1β, pro-caspase-1, and apoptosis-associated speck-like protein containing a CARD (ASC) transformed human 293T cells to determine the mechanism via 2-E+2-3a-induced mROS activated the NLRP3-I-inflammasome.

Findings

The results suggest that SARS-CoV-2 viroporin proteins E and Orf3a expression in human 293T cells led to elevated cytosolic and mitochondrial calcium (Ca++) uptake by the mitochondrial calcium uniporter (MCU) sensitive to the MCU inhibitor 11 (MCUi11). Further, the viroporin proteins E and Orf3a-induced mitochondrial Ca++ hike in the human 293T cells caused the activation of α-ketoglutarate and pyruvate, leading to excess nicotinamide adenine dinucleotide+ hydrogen (NADH), which further triggered mitochondrial reactive oxygen species (mROS) generation.

In addition, the mROS elevation was inhibited by the treatment with either metalloporphyrin (Mn III) tetrakis (4-benzoic acid) porphyrin (MnTBAP) or mitochondrially targeted catalase (mCAT).

The expression of SARS-CoV-2 viroporin proteins E and Orf3a in the macrophages of the human 293T cells expressing NLRP3-I-inflammasome and the bacterial lipopolysaccharide (LPS)/nigericin-treated THP1 cells with viroporin proteins E and Orf3a expression vector demonstrated increased secretion of NLRP3-I-activated IL-1β secretion. Further, MnTBAP or mCAT treatment of LPS-nigericin treated THP1 macrophages and 293T cells expressing NLRP3-I-inflammasome impaired IL-1β secretion.  

The treatment of the 2-E+2-3a transformed and LPS-nigericin treated THP1 macrophages with mitochondrial permeability pore (mtPTP) inhibitor called N-methyl-4-isoleucine-cyclosporin (NIM811) extinguished the secretion of IL-1β, suggesting that the oxidized mitochondrial factor, oxidized mitochondrial deoxyribonucleic acid (Ox-mtDNA) reached the NLRP3-I via mtPTP.

Conclusions

The study findings indicate that the co-expression of the SARS-CoV-2 viroporin proteins E and Orf3a in human 293T cells stimulate the leakage of Ca++ into the cytosol, resulting in mitochondrial as well as cytosolic elevated Ca++ levels. Further, the SARS-CoV-2 2-E+2-3a-mediated elevation of mitochondrial Ca++ leads to a rise in mROS production, which activates the NLRP3-I through mtPTP transport of Ox-mtDNA, triggering IL-1β secretion.

According to the authors, this was the first study showing that the oxidized mitochondrial factor reaches the NRLP3-I-inflammasome via the mtPTP. However, the team failed to identify the oxidized mitochondrial factor and relied on previous reports indicating Ox mtDNA as the oxidized mitochondrial factor.

Previous reports have indicated that the antioxidants such as glutathione, catalase, and N-acetyl cysteine (NAC) can reduce SARS-CoV-2 propagation and pathology. The current study expands this inference by proving that a high level of therapeutic potential against SARS-CoV-2 was associated with the mitochondrially targeted antioxidants, such as eukaryotic-8 (EUK-8) and EUK-134, and MnTBAP, or mtPTP inhibitors like NIM811.

In detail, the study suggests that enhancing the mitochondrial antioxidant defenses via genetic expression of mCAT or treatment with the pharmacological mROS scavenger MnTBAP detoxifies the SARS-CoV-2 viroporin proteins E and Orf3a-induced mROS and inhibits the activation of the NLRP3-I, thereby mitigating the cytokine storm associated with the severe form of SARS-CoV-2 infection.

Overall, the study illustrates that SARS-CoV-2 engages with the NLRP3-I-inflammasome through the 2-E+2-3a viroporin manipulation of mtPTP.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 12 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Shanet Susan Alex

Written by

Shanet Susan Alex

Shanet Susan Alex, a medical writer, based in Kerala, India, is a Doctor of Pharmacy graduate from Kerala University of Health Sciences. Her academic background is in clinical pharmacy and research, and she is passionate about medical writing. Shanet has published papers in the International Journal of Medical Science and Current Research (IJMSCR), the International Journal of Pharmacy (IJP), and the International Journal of Medical Science and Applied Research (IJMSAR). Apart from work, she enjoys listening to music and watching movies.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Susan Alex, Shanet. (2023, May 12). SARS-CoV-2 viroporins mediate cytokine storm via mitochondrial permeability transition pore. News-Medical. Retrieved on May 24, 2024 from https://www.news-medical.net/news/20220224/SARS-CoV-2-viroporins-mediate-cytokine-storm-via-mitochondrial-permeability-transition-pore.aspx.

  • MLA

    Susan Alex, Shanet. "SARS-CoV-2 viroporins mediate cytokine storm via mitochondrial permeability transition pore". News-Medical. 24 May 2024. <https://www.news-medical.net/news/20220224/SARS-CoV-2-viroporins-mediate-cytokine-storm-via-mitochondrial-permeability-transition-pore.aspx>.

  • Chicago

    Susan Alex, Shanet. "SARS-CoV-2 viroporins mediate cytokine storm via mitochondrial permeability transition pore". News-Medical. https://www.news-medical.net/news/20220224/SARS-CoV-2-viroporins-mediate-cytokine-storm-via-mitochondrial-permeability-transition-pore.aspx. (accessed May 24, 2024).

  • Harvard

    Susan Alex, Shanet. 2023. SARS-CoV-2 viroporins mediate cytokine storm via mitochondrial permeability transition pore. News-Medical, viewed 24 May 2024, https://www.news-medical.net/news/20220224/SARS-CoV-2-viroporins-mediate-cytokine-storm-via-mitochondrial-permeability-transition-pore.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
LVRNA009 mRNA vaccine shows long-term efficacy against SARS-CoV-2 variants